Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937263 | 0.90 | PARP10 (0.40) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL11937258 | 0.87 | PARP10 (0.41) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL11937256 | 0.87 | PARP10 (0.41) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL11937260 | 0.86 | PARP10 (0.40) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL11937264 | 0.85 | PARP10 (0.40) | PARP10PARP14HIF1APARP15 | |
| SCHEMBL11937265 | 0.85 | PARP10 (0.40) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL10087879 | 0.85 | PARP10 (0.42) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL10087888 | 0.84 | HIF1A (0.45) | PARP10PARP14HIF1APARP15MAOB | |
| SCHEMBL11937268 | 0.84 | HIF1A (0.40) | HIF1AKDM4ETDP1MEN1KMT2A | |
| SCHEMBL11937273 | 0.83 | HIF1A (0.46) | HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | disclosed |
| US-8227456-B2 | Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-07-24 | — | — | US | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-7879835-B2 | treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | ARSA, BMP2, BMP1 | PARP10 2768/4885PARP14 3546/4885HIF1A 1136/4885 |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | CYP24A1, SOST, ACP3 | PARP10 3461/4885PARP14 3968/4885HIF1A 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.